Alto Neuroscience's ALTO-300, a novel biomarker-based antidepressant, advances in Phase 2b trial for Major Depressive Disorder with topline results expected by mid-2026.
Alto Neuroscience's ALTO-100 failed to meet its primary endpoint in a Phase 2b trial for major depressive disorder (MDD), as measured by the MADRS scale.